---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-095442"
form_type: "8-K"
ticker: null
cik: "0001900520"
company_name: "Lomond Therapeutics Holdings, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:55:51.945463+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# SPAC Venetian-1 completes reverse merger with biotech Lomond; raises $43.9M in PIPE

## Summary
- Merger closed Nov 1, 2024; Venetian-1 changed name to Lomond Therapeutics Holdings, Inc.
- Legacy Lomond stockholders received 14,420,383 shares; 3,625,000 pre-merger shares forfeited.
- Private placement raised $43.9M: 8,241,375 shares at $4.00 plus SAFE conversions at $3.20/$3.60.
- Options for 4,329,617 shares at $1.30 assumed; 2024 Equity Incentive Plan adopted.
- Lock-up agreements for directors/officers; company must file resale registration statement within 20 trading days.

## SEC filing metadata
- accession: 0001213900-24-095442
- form_type: 8-K
- cik: 0001900520
- company_name: Lomond Therapeutics Holdings, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.01, 3.02, 1.01, 3.03, 4.01, 5.01, 5.02, 5.03, 5.06, 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1900520/000121390024095442/0001213900-24-095442-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1900520/000121390024095442/ea0219762-8k_lomond.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-095442
- JSON: https://secwatch.observer/filing/0001213900-24-095442.json
- Plain text: https://secwatch.observer/filing/0001213900-24-095442.txt

## Key facts
- Governance Changes
  Lomond Therapeutics Holdings, Inc.: Amended and restated bylaws in their entirety (effective 2024-11-01).
  - Change: bylaw amendment
  - Effective: 2024-11-01
  source text: Amended and Restated Bylaws Prior to the Merger, on November 1, 2024, we amended and restated our bylaws in their entirety.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1900520/000121390024095442/0001213900-24-095442-index.htm
- Governance Changes
  Lomond Therapeutics Holdings, Inc.: Amended and restated certificate of incorporation (effective 2024-11-01).
  - Change: charter amendment
  - Effective: 2024-11-01
  source text: Amended and Restated Certificate of Incorporation Prior to the Merger, our board of directors approved the amendment and restatement of our certificate of incorporation on November 1, 2024, and stockholders holding 100% of the then outstanding shares of our common stock approved the amendment and restatement to our certificate of incorporation on November 1, 2024, which became effective when filed with the Secretary of State of the State of Delaware on November 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1900520/000121390024095442/0001213900-24-095442-index.htm
- Governance Changes
  Lomond Therapeutics Holdings, Inc.: Ceased to be a shell company as a result of the Merger.
  - Change: shell status
  source text: Prior to the Merger, we were a "shell company" (as such term is defined in Rule 12b-2 under the Exchange Act). As a result of the Merger, we have ceased to be a shell company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1900520/000121390024095442/0001213900-24-095442-index.htm
- M&A Transactions
  Lomond Therapeutics Holdings, Inc. completed an acquisition involving Lomond Therapeutics, Inc. (closed 2024-11-01).
  - Action: acquisition
  - Counterparty: Lomond Therapeutics, Inc.
  - Closing: 2024-11-01
  source text: Acquisition Sub merged with and into Legacy Lomond, with Legacy Lomond continuing as the surviving corporation and our wholly-owned subsidiary.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1900520/000121390024095442/0001213900-24-095442-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.